Key result
Carrying the A allele of the CCL4-rs1719217 polymorphism was associated with an increased risk of developing pancreatic ductal adenocarcinoma (OR 1.12; 95% CI 1.06-1.18; P=3.34×10-5).
Why the study?
Little is known about the genetic variability of genes that regulate inflammation and the risk of pancreatic ductal adenocarcinoma.
Is the A allele of the CCL4-rs1719217 polymorphism associated with an increased risk of developing pancreatic ductal adenocarcinoma?
Case-Control (n=14,270)
Is the A allele of the CCL4-rs1719217 polymorphism associated with an increased risk of developing pancreatic ductal adenocarcinoma?
Odds Ratio: 1.12 (95% CI 1.06–1.18)
p-value: p=3.34 × 10-5
The A allele of the CCL4-rs1719217 polymorphism is significantly associated with an increased risk of developing pancreatic ductal adenocarcinoma.
Inflammation gene variants may associate with PDAC risk; leaves open replication and causal inference in prospective studies.
There is overwhelming evidence that inflammation plays a key role in the pathogenesis of cancer and its progression. Inflammation is regulated through a complex network of genes and polymorphic variants in these genes have been found to be associated to risk of various human cancers, alone or in combination with environmental variables. Despite this, not much is known on the genetic variability of genes that regulate inflammation and risk of pancreatic ductal adenocarcinoma (PDAC). We performed a two-phase association study considering the genetic variability of 76 genes that are key players in inflammatory response. We analysed tagging single nucleotide polymorphisms (SNPs) and regulatory SNPs on 7207 PDAC cases and 7063 controls and observed several associations with PDAC risk. The most significant association was between the carriers of the A allele of the CCL4-rs1719217 polymorphism, which was reported to be also associated with the expression level of the CCL4 gene, and increased risk of developing PDAC (odds ratio = 1.12, 95% confidence interval = 1.06-1.18, P = 3.34 × 10-5). This association was significant also after correction for multiple testing, highlighting the importance of using potentially functional SNPs in order to discover more genetic variants associated with PDAC risk.
No takes yet. Share an insight, caveat, or question.
Gentiluomo et al. (2019) conducted a case-control in Pancreatic ductal adenocarcinoma (PDAC) (n=14,270). A allele of the CCL4-rs1719217 polymorphism vs. Non-carriers was evaluated on Risk of developing PDAC (OR 1.12, 95% CI 1.06-1.18, p=3.34 × 10-5). Carrying the A allele of the CCL4-rs1719217 polymorphism was associated with an increased risk of developing pancreatic ductal adenocarcinoma (OR 1.12; 95% CI 1.06-1.18; P=3.34×10-5).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: